The purpose of this study is to determine the effectiveness and safety of Apatinib for patients with Recurrent or Recurrent High-grade Glioma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
Overall Survival(OS)
The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
Time frame: 24 month
Progress-free Survival(PFS)
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Time frame: 24month
Objective Response Rate(ORR)
Proportion of patients with reduction in tumor burden of a predefined amount
Time frame: 6month
EORTC QLQ-C30
The EORTC Quality of Life questionnaires are developed to assess the quality of life of cancer patients.
Time frame: 24month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.